---
canonical_url: https://www.stockexpertai.com/earnings/biib
last_updated: 2026-05-09T12:17:12.615Z
---

# Biogen Inc. (BIIB) Q4 FY2026 Earnings Preview

> This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T12:17:12.092Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $193.45 (▲ 1.08%) | fmp:quote |
| Market Cap | $28.6B | fmp:profile |
| 52w range | $119.18 – $202.41 | fmp:quote |
| Earnings | Thu 30 Jul | fmp:earnings-history |
| EPS estimate | $3.33 (-39% YoY) | fmp:earnings-estimate |
| Revenue estimate | $2.4B | fmp:earnings-estimate |
| Beat streak | 8/4 | fmp:earnings-history |
| Rating | A- (overall 4/5) | fmp:ratings |
| Analyst median target | $214 (+10.6% upside) | fmp:price-target-consensus |
| MoonshotScore | 50/100 | derived |
| Council | 2/6 bullish | derived |
| Munger verdict | Fairly Valued | derived |

## Biogen Inc. — Q4 FY2026 Expectations

Q4 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$2.4B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$3.33</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 8 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** A- · **Stance:** HOLD · **Council:** 2/6 · **Moonshot:** 50

= MoonshotScore <strong>50</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="9-pillar formula">[9-pillar formula]</sup> + Council <strong>2/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (5 metrics)

### 1. Growth Products Q1 Revenue

Growth products generated $850 million in the first quarter of 2026, up 12%.

> "And by shifting that to our growth products, I think one of the things you see here on the first slide is that the growth products are now generating $850 million in the first quarter, and that's up 12%."
> — Christopher Viehbacher, CEO, Investor Focus · Q1 FY2026

### 2. Skyclarys Q1 Revenue

SKYCLARYS saw sequential global patient demand growth with first quarter 2026 global revenue of $151 million, representing 22% growth year-over-year.

> "SKYCLARYS saw sequential global patient demand growth with first quarter 2026 global revenue of $151 million, representing 22% growth year-over-year."
> — Robin Kramer, CFO, Investor Focus · Q1 FY2026

### 3. Leqembi Market Revenue

LEQEMBI market revenue was $168 million for the first quarter of 2026, up 74% year-over-year.

> "LEQEMBI market revenue was $168 million for the first quarter of 2026, up 74% year-over-year."
> — Robin Kramer, CFO, Investor Focus · Q1 FY2026

### 4. Free Cash Flow Q1

We generated $594 million of free cash flow in the first quarter of 2026

> "We generated $594 million of free cash flow in the first quarter of 2026"
> — Robin Kramer, CFO, Investor Focus · Q1 FY2026

### 5. Apellis Acquisition Accretive

We do expect the acquisition to be accretive in 2027. And when you look out over the next few years, this materially increases Biogen's EPS outlook.

> "So as we look at this, -- we do expect the acquisition to be accretive in 2027. And when you look out over the next few years, this materially increases Biogen's EPS outlook."
> — Christopher Viehbacher, CEO, Investor Focus · Q1 FY2026


## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 0.0 | weak | Q1 vs Q2: growth negative (-6.3%, contraction) |
| Gross Margin | 7.0 | strong | Q1: very high margin (73.3%, software/cloud territory) |
| Operating Leverage | 2.0 | weak | op margin healthy (16.0%) |
| Cash Runway | 10.0 | strong | FCF very strong ($0.7B, 13.6× CapEx) |
| R&D Intensity | 3.0 | weak | very high R&D (20.1%, margin pressure risk) |
| Price Momentum | 7.0 | strong | RSI 59.4 positive momentum, 50d above |
| News Sentiment | 6.0 | medium | majority buy (55%) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +10.6% |
| Ken Griffin | bull | flow · 50d MA above |
| Jim Simons | neutral | quant · RSI 59 |
| Klarman | neutral | value · target upside +10.6% |
| Buffett | neutral | quality · ROE score 3/5 |
| Munger | neutral | valuation · target upside +10.6% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Fairly Valued
- **Financial Health:** Strong
- **Margin of Safety:** Moderate
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Tight

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 59.4 — yükselişte nötr — overbought sınırının altında, momentum pozitif
- **50d MA:** $185 — hisse %4.8 üstünde — kısa vadeli destek
- **200d MA:** $166 — hisse %16.5 üstünde — uzun vadeli destek
- **Volume (10d):** -13%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q2 FY25 | $5.47 | $3.90 | BEAT | +3.1% |
| Q3 FY25 | $4.81 | $3.88 | BEAT | +3.1% |
| Q4 FY25 | $1.99 | $1.63 | BEAT | -3.7% |
| Q1 FY26 | $3.57 | $2.95 | +21.0% EPS | -2.6% |

Q1 (April 29, 2026): EPS $3.57 vs $2.95 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +21.0% beat. D+1 movement: -2.6%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q4 EPS > $3.33 + CapEx discipline**

Threshold: EPS > $3.33<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $214<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $260<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $3.33 + CapEx < $51.2M**

Threshold: EPS ≈ $3.33<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q4 CapEx < $51.2M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $193<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $214<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $3.23 or CapEx ≥ $51.2M**

Threshold: EPS < $3.23<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $193 below SMA200 $166<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $141<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q1: EPS $3.57 vs $2.95 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock -2.6% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q1 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26

### CapEx shock
Q1 CapEx $51.2M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q1 op margin 16.0%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q4 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $214 (+10.6% upside vs current $193)
- **High / Low:** $260 / $143
- **Buy / Hold / Sell:** 21 / 16 / 1
- **Analyst count:** 13 (last quarter), 124 all-time

## Additional Transcript Insights

### 1. growth_products_q1_revenue

**Claim:** Growth products generated $850 million in the first quarter of 2026, up 12%.

**Evidence (transcript):** "And by shifting that to our growth products, I think one of the things you see here on the first slide is that the growth products are now generating $850 million in the first quarter, and that's up 12%."

**Numbers:** $850 million, 12%

### 2. leqembi_market_revenue

**Claim:** LEQEMBI market revenue was $168 million for the first quarter of 2026, up 74% year-over-year.

**Evidence (transcript):** "LEQEMBI market revenue was $168 million for the first quarter of 2026, up 74% year-over-year."

**Numbers:** $168 million, 74%

### 3. skyclarys_q1_revenue

**Claim:** SKYCLARYS saw sequential global patient demand growth with first quarter 2026 global revenue of $151 million, representing 22% growth year-over-year.

**Evidence (transcript):** "SKYCLARYS saw sequential global patient demand growth with first quarter 2026 global revenue of $151 million, representing 22% growth year-over-year."

**Numbers:** $151 million, 22%

### 4. apellis_acquisition_accretive

**Claim:** We do expect the acquisition to be accretive in 2027. And when you look out over the next few years, this materially increases Biogen's EPS outlook.

**Evidence (transcript):** "So as we look at this, -- we do expect the acquisition to be accretive in 2027. And when you look out over the next few years, this materially increases Biogen's EPS outlook."

**Numbers:** 2027

### 5. free_cash_flow_q1

**Claim:** We generated $594 million of free cash flow in the first quarter of 2026

**Evidence (transcript):** "We generated $594 million of free cash flow in the first quarter of 2026"

**Numbers:** $594 million, 2026


---

*Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*